One day before comments closed on the Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights, published by the National Institute of Standards & Technology (NIST) and the Department of Commerce last month, the Department of Health and Human Services (HHS) denied an appeal of a decision not to march in on the blockbuster prostate cancer drug, Xtandi®.
Recent Posts
- Fox Succeeds in Scrapping Machine Learning Claims at CAFC Under 101
- Other Barks & Bites for Friday, April 18: CAFC Affirms Ineligibility of Machine Learning Claims; EPO’s Campinos Issues Opinion on Intervener Appeals; USPTO Ends Climate Change Mitigation Program
- In Latest Antitrust Blow for Google, Judge Finds Search Giant Monopolizes Certain Ad Tech Markets
- New USPTO Group to Crack Down on Threats to U.S. Patent System
- IP, Globalization and the Future of Supply Chains: A Conversation with Sonja London | IPWatchdog Unleashed